Close

Edwards Lifesciences (EW) Receives Broader FDA Coverage for Sapien XT and Sapien 3

Go back to Edwards Lifesciences (EW) Receives Broader FDA Coverage for Sapien XT and Sapien 3

Evercore Says Approval of Edwards' (EW) SAPIEN 3 Anticipated; Medtronic's CoreValve Expected in Early 2017

August 18, 2016 3:32 PM EDT

Evercore ISI affirms Edwards Lifesciences (NYSE: EW) at Hold with a price target of $115 after the company announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who have been determined by a Heart Team to be at intermediate risk for open-heart... More

Edwards Lifesciences (EW) Announces Expanded Indication From FDA for SAPIEN 3 Transcatheter Heart Valve

August 18, 2016 3:01 PM EDT

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who have been determined by a Heart Team to be at intermediate risk for open-heart surgery. The SAPIEN 3 valve is the first transcatheter aortic valve replacement (TAVR) therapy to obtain this indication in the United States.

"The SAPIEN 3 valve has set a new... More